Miguel Sieler Head of Neovacs : "We develop groundbreaking technology".
Presentation and analysis about Neovacs products and achievements

18 juin 2014 17 h 38 min
+ de videos
541
Views
Loading the player...

Neovacs, (Alternext Paris: ALNEV), is a leader in active immunotherapies for the treatment of autoimmune diseases. The company will participate to the first annual “French Life Sciences Days”, a major event that will bring together French biotech and medtech companies listed on the NYSE Euronext exchange, with member of the French and North American financial communauty. Miguel Sieler CEO of Neovacs explained the strategy of the company for US investors. 

Main discussion in this video :

What Neovacs is developing exactly ?

At what development stage are the Neovacs products ?

Neovacs has 4 preclinical programs, which is the most advanced ?

Why are you coming to New York ?

THIS VIDEO HAS BEEN PRODUCED BY LA BOURSE ET LA VIE TV EDITOR OF Web Tv www.labourseetlavie.com

Print Friendly, PDF & Email